Integrated Filing — IndAS



General information about company

Scrip Code 543318
NSE Symbol CLEAN
MSEI Symbol NOTLISTED
ISIN INE227W01023
Name of company CLEAN SCIENCE AND TECHNOLOGY LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2026
Date of end of financial year 31-03-2027
Date of board meeting when results were approved 31-10-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 17-10-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Second quarter
Nature of report standalone or consolidated Consolidated
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Unaudited
Segment Reporting Single segment
Description of single segment Speciality Chemicals
Start date and time of board meeting 31-10-2026   12:00:00
End date and time of board meeting 31-10-2026   14:20:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Not applicable



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Consolidated Consolidated
1 Income
Revenue from operations 29,939.00 56,782.20
Other income 566.40 2,788.20
Total income 30,505.40 59,570.40
2 Expenses
(a) Cost of materials consumed 14,893.20 27,578.00
(b) Purchases of stock-in-trade 0.00 0.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (2,118.00) (4,312.10)
(d) Employee benefit expense 1,597.10 3,259.90
(e) Finance costs 193.70 198.90
(f) Depreciation, depletion and amortisation expense 2,137.70 4,242.40
(f) Other Expenses
1 Other expenses 6,360.10 11,406.60
Total other expenses 6,360.10 11,406.60
Total expenses 23,063.80 42,373.70
3 Total profit before exceptional items and tax 7,441.60 17,196.70
4 Exceptional items 0.00 0.00
5 Total profit before tax 7,441.60 17,196.70
6 Tax expense
7 Current tax 2,022.00 4,152.10
8 Deferred tax (152.90) 137.10
9 Total tax expenses 1,869.10 4,289.20
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 5,572.50 12,907.50
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 5,572.50 12,907.50
17 Other comprehensive income net of taxes 6.00 12.10
18 Total Comprehensive Income for the period 5,578.50 12,919.60
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent 0.00 0.00
Total profit or loss, attributable to non-controlling interests 0.00 0.00
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent 0.00 0.00
Total comprehensive income for the period attributable to owners of parent non-controlling interests 0.00 0.00
21 Details of equity share capital
Paid-up equity share capital 1,062.80 1,062.80
Face value of equity share capital 1 1
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 0 0
Diluted earnings (loss) per share from continuing operations 0 0
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 5.24 12.14
Diluted earnings (loss) per share from discontinued operations 5.24 12.14
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 5.24 12.14
Diluted earnings (loss) per share from continuing and discontinued operations 5.24 12.14
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) 1. The Statement has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards 34 Interim Financial Reporting (Ind AS 34) prescribed under Section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules, 2015 as amended from time to time and the provisions of the Companies Act 2013 and other accounting principles. 2. The above results have been subjected to Limited Review by the statutory auditors of the Company in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended and have been reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at its meeting held on October 31, 2026. 3. Standalone information: Particulars Quarter Ended Half Year Ended Sep 26 Apr to Sep 26 Revenue 2329.32 4400.36 Profit before tax 739.14 1714.37 Profit for the period / year 553.51 1286.42 Other comprehensive income 0.61 1.21 Total comprehensive income 554.12 1287.63 4. The Group is exclusively engaged in the business of manufacturing of organic chemicals. This in the context of the Ind AS 108 Operating Segments, is considered to constitute one single primary segment. 5. During the half year ended September 30, 2026, 6,822 equity shares of Rs. 1/- each fully paid-up, were allotted upon exercise of the vested stock options pursuant to the Company's Employee Stock Option Scheme, 2021 (ESOP 2021). 6. Clean-Fino Chem Limited (the “Subsidiary”), has entered into an agreement on July 16, 2026 for a long-term strategic collaboration with Geneus Chem AG, a company incorporated under the laws of Switzerland. The agreement is for manufacturing and supply of advanced grades of HALS Products on a worldwide exclusive basis and includes, inter alia, provisions relating to minimum offtake commitments and pricing mechanism. In lieu of above collaboration, Geneus Chem AG has agreed to issue warrants to the Subsidiary which are exercisable within a period of four years from the date of issue. Upon exercise of the share warrants, the Subsidiary will acquire 25% of the share capital of Geneus Chem AG on a fully diluted basis and will be required to pay a nominal price per common share to Geneus Chem AG. Subsequent to the half year ended September 30, 2026, the Subsidiary has successfully conducted and completed the product trails for these advanced grades of HALS Products. 7. During the quarter, the Maharashtra GST Department conducted search and inspection proceedings under Section 67 of the Maharashtra GST Act, 2017 at the registered office and manufacturing units of the Company and its wholly owned subsidiary, which concluded on September 29, 2026. Pursuant to the said proceedings, the Department has indicated GST liability of Rs.99.85 million under reverse charge mechanism, eligible for input tax credit, together with an interest liability and certain non-creditable tax liabilities aggregating to Rs. 20.20 million. However, discussions with the GST authorities in relation to the determination of the final liability and the related interest are ongoing and the amounts have not yet been finally concluded/ appropriated by the Department. The Company has deposited amounts corresponding to the aforesaid RCM liability and related interest in its GST electronic cash ledger. Based on its assessment of the matter, the Company has recognized a provision towards the interest and certain non-creditable tax liabilities aggregating to Rs. 20.20 million in the consolidated financial results for the quarter ended September 30, 2026. 8. Clean Science and Technology Limited (CSTL), through its wholly owned subsidiary Clean Fino-Chem Limited (CFCL), has incorporated Clean Science International B.V. in the Netherlands. The incorporation is part of the Group's strategic initiative to strengthen its international presence and support its growing business activities in Europe. 9. The consolidated results of the Group are available on the Company's website, www.cleanscience.co.in and also on the website of the BSE Limited, www.bseindia.com and National Stock Exchange of India Limited, www.nseindia.com, where the shares of the Company are listed.



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2026
Date of end of reporting period 30-09-2026
Whether results are audited or unaudited Unaudited
Nature of report standalone or consolidated Consolidated
Assets
1 Non-current assets
Property, plant and equipment 73,601.40
Capital work-in-progress 15,635.00
Investment property 0.00
Goodwill 0.00
Other intangible assets 633.50
Intangible assets under development 0.00
Biological assets other than bearer plants 0.00
Investments accounted for using equity method 0.00
Non-current financial assets
Non-current investments 4,662.40
Trade receivables, non-current 0.00
Loans, non-current 0.00
Other non-current financial assets
1 Other non-current financial assets 172.70
Total of other non-current financial assets 172.70
Total non-current financial assets 4,835.10
Deferred tax assets (net) 1,255.50
Other non-current assets
1 Other non-current assets 758.80
Total of other non-current assets 758.80
Total non-current assets 96,719.30
2 Current assets
Inventories 22,154.40
Current financial asset
Current investments 35,009.40
Trade receivables, current 26,290.00
Cash and cash equivalents 1,614.40
Bank balance other than cash and cash equivalents 396.60
Loans, current 0.00
Other current financial assets
Total of other current financial assets 88.00
Total current financial assets 63,398.40
Current tax assets (net) 24.10
Other current assets
1 Other current assets 9,742.00
Total of other current assets 9,742.00
Total current assets 95,318.90
3 Non-current assets classified as held for sale 0.00
4 Regulatory deferral account debit balances and related deferred tax Assets 0.00
Total assets 1,92,038.20
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 1,062.80
Other equity 1,66,119.70
Total equity attributable to owners of parent 1,67,182.50
Non controlling interest 0.00
Total equity 1,67,182.50
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 0.00
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0.00
Total Trade payable 0.00
Other non-current financial liabilities
1 Other non-current financial liabilities 391.60
Total of other non-current financial liabilities 391.60
Total non-current financial liabilities 391.60
Provisions, non-current 0.00
Deferred tax liabilities (net) 3,123.20
Deferred government grants, Non-current 0.00
Other non-current liabilities
1 Other non-current liabilities 0.00
Total of other non-current liabilities 0.00
Total non-current liabilities 3,514.80
Current liabilities
Current financial liabilities
Borrowings, current 0.00
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 398.50
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 15,939.80
Total Trade payable 16,338.30
Other current financial liabilities
1 Other current financial liabilities 2,570.70
Total of other current financial liabilities 2,570.70
Total current financial liabilities 18,909.00
Other current liabilities 1,010.50
1 Other current liabilities 1,010.50
Total of other current liabilities 1,010.50
Provisions, current 217.90
Current tax liabilities (Net) 1,203.50
Deferred government grants, Current
Total current liabilities 21,340.90
3 Liabilities directly associated with assets in disposal group classified as held for sale
4 Regulatory deferral account credit balances and related deferred tax liability
Total liabilities 24,855.70
Total equity and liabilites 1,92,038.20
Disclosure of notes on assets and liabilities



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-07-2026 01-04-2026
Date of end of reporting period 30-09-2026 30-09-2026
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Consolidated Consolidated
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Consolidated Consolidated
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Remeasurements of post employment benefit obigations. 8.00 16.10
Total Amount of items that will not be reclassified to profit and loss 8.00 16.10
2 Income tax relating to items that will not be reclassified to profit or loss 2.00 4.00
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss
5 Total Other comprehensive income 6.00 12.10



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2026
B Date of end of reporting period 30-09-2026
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Consolidated
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 17,196.70
Adjustments for reconcile profit (loss)
Adjustments for finance costs 198.90
Adjustments for decrease (increase) in inventories (6,782.20)
Adjustments for decrease (increase) in trade receivables, current (5,480.40)
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets (1,161.00)
Adjustments for decrease (increase) in other non-current assets 0.00
Adjustments for other financial assets, non-current (0.90)
Adjustments for other financial assets, current 2.20
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current 4,767.70
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities 152.00
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 4,242.40
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0.00
Adjustments for provisions, current 17.20
Adjustments for provisions, non-current 0.00
Adjustments for other financial liabilities, current 358.00
Adjustments for other financial liabilities, non-current 0.00
Adjustments for unrealised foreign exchange losses gains (287.80)
Adjustments for dividend income 0.00
Adjustments for interest income 198.30
Adjustments for share-based payments 103.10
Adjustments for fair value losses (gains) (162.30)
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow (796.90)
Other adjustments to reconcile profit (loss) (1,272.90)
Other adjustments for non-cash items (267.90)
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) (6,569.10)
Net cash flows from (used in) operations 10,627.60
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 3,441.40
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities 7,186.20
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 0.00
Other cash receipts from sales of equity or debt instruments of other entities 50,593.10
Other cash payments to acquire equity or debt instruments of other entities 48,451.90
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 627.50
Purchase of property, plant and equipment 7,639.00
Proceeds from sales of investment property 0.00
Purchase of investment property 0.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 0.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 1,623.00
Purchase of other long-term assets 1,019.00
Cash advances and loans made to other parties 0.00
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 0.00
Interest received 303.30
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) investing activities (3,963.00)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 0.00
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 34.10
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 0.00
Repayments of borrowings 0.00
Payments of lease liabilities 0.00
Dividends paid 4,251.40
Interest paid 198.50
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) financing activities (4,415.80)
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes (1,192.60)
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 5.00
Net increase (decrease) in cash and cash equivalents (1,187.60)
Cash and cash equivalents cash flow statement at beginning of period 2,802.00
Cash and cash equivalents cash flow statement at end of period 1,614.40